Indicazioni al trattamento chirurgico integrato delle carcinosi peritoneali di origine colorettale: esperienza della società Italiana di terapie integrate locoregionali in oncologia.

Translated title of the contribution: Indications for integrated surgical treatment of peritoneal carcinomatosis of colorectal origin: experience of the Italian Society of Locoregional Integrated Therapy in Oncology

F. Cavaliere, P. Perri, C. R. Rossi, P. L. Pilati, M. De Simone, M. Vaira, M. Deraco, F. Di Filippo

Research output: Contribution to journalArticlepeer-review

Abstract

A multicentric prospective study has been carried on 69 patients affected by peritoneal carcinomatosis from colorectal cancer. Patients have been treated by cytoreductive surgery and intraoperative hyperthermic chemoperfusion. CC 0-1 has been achieved in 82%. Major morbidity and mortality was respectively 21.7% and 2.9%. Three years overall survival was 26.7% for all series. Difference in survival evaluating CC 0-1 vs CC 2 patients and PCI <or = 10 vs > 10 was statistically significant. Evaluating only patients CC 0-1 and PCI <or = 10 overall survival rised up to 44.7% at 4 years. A smaller subgroup of patients with a disease-free interval to peritoneal carcinomatosis > or = 2-year showed a 50% disease-free survival at 5 years. In conclusion PCI <or = 10, complete or optimal cytoreduction feasibility and disease-free interval have to be considered for the patients selection to the integrate treatment.

Translated title of the contributionIndications for integrated surgical treatment of peritoneal carcinomatosis of colorectal origin: experience of the Italian Society of Locoregional Integrated Therapy in Oncology
Original languageItalian
Pages (from-to)21-23
Number of pages3
JournalTumori
Volume89
Issue number4 Suppl
Publication statusPublished - Jul 2003

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Indications for integrated surgical treatment of peritoneal carcinomatosis of colorectal origin: experience of the Italian Society of Locoregional Integrated Therapy in Oncology'. Together they form a unique fingerprint.

Cite this